Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, 5-FU, IL-2 and IFN-alpha in Renal Cell Cancer
NCT00003664Phase 2Unknown
- Sponsor
- Cancer Biotherapy Research Group
- Start
- Oct 1998
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, fluorouracil, aldesleukin and interferon alfa in renal cell carcinoma (RCC), sponsored by Cancer Biotherapy Research Group. Primary endpoint: Toxic effects. Status: unknown.
02
Drugs
gemcitabinefluorouracilaldesleukininterferon alfa
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00003664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003664.